Moderna Reports Q4 Loss, Tops Wall Street Estimates
CAMBRIDGE, Mass. – Moderna Inc. (MRNA) reported a fourth-quarter loss of $1.12 billion, or $2.91 per share. Excluding non-recurring expenses, the Cambridge, Massachusetts-based company posted a loss of $2.50 per share.
The results exceeded analysts' expectations. A survey of 12 analysts by Zacks Investment Research projected a loss of $2.69 per share.
Revenue for the period reached $966 million, also beating Street forecasts. Nine analysts surveyed by Zacks had estimated revenue of $956.1 million.
For the full year, Moderna reported a loss of $3.56 billion, or $9.28 per share, on revenue of $3.24 billion.
Looking ahead, Moderna expects full-year revenue in the range of $1.5 billion to $2.5 billion.